Several studies have reported that NSCLC patients with high blood-based TMB (bTMB) could obtain better efficacy from PD-1/PD-L1 inhibitor therapy than patients whose bTMB is low [22–25]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.